Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2021-01-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board's approval, investment purpose, product types, risk control measures, and opinions from the supervisory board, independent directors, and the sponsoring institution. The document is about the company's financing activities related to the management of raised funds, not a full financial report or audit. It is a regulatory announcement about capital usage and financing activities, specifically about cash management of idle raised funds. The document length is under 5,000 characters and is an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-21 Chinese
江苏浩欧博生物医药股份有限公司关于变更公司注册资本、公司类型、修订公司章程并办理工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in the company's registered capital, company type, and amendments to the company's articles of association. It references approvals from regulatory bodies and details about the company's stock issuance and listing on the Shanghai Stock Exchange. The document does not contain full financial statements or detailed financial performance data but rather informs about corporate structural changes and regulatory approvals. It is not a full annual or interim report, nor an earnings release or audit report. The content fits best with a Regulatory Filing (RNS) as it is a formal announcement of corporate changes and regulatory compliance without substantive financial data or report content.
2021-01-21 Chinese
江苏浩欧博生物医药股份有限公司章程
Governance Information Classification · 95% confidence The document is titled as the Articles of Association (章程) of 江苏浩欧博生物医药股份有限公司, dated January 2021. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, meetings, voting procedures, and other governance-related rules. There is no indication that this is a financial report, earnings release, or announcement. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2021-01-21 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled as the "章程 (草案)" which translates to "Articles of Association (Draft)" for 江苏浩欧博生物医药股份有限公司. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, shareholder meetings, voting procedures, and other governance-related rules. There is no financial data, earnings information, audit results, or capital financing updates. Instead, it is a governance document outlining the company's internal rules and regulations. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the actual governance document, not just an announcement. Therefore, the correct classification is CGR with high confidence.
2021-01-11 Chinese
首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) and listing of Jiangsu HOB Biotech Group Corp., Ltd. on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the company's background, shareholding structure, risk factors, stock issuance details, lock-up periods, and regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document is titled as a "上市公告书" which translates to "Listing Announcement" or "IPO Listing Prospectus". It is not a financial report like an annual or quarterly report, nor is it a simple announcement of voting results or a proxy statement. It is a formal regulatory filing announcing the company's stock listing and IPO details. Given the detailed nature and regulatory context, this fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-01-11 Chinese
首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus (招股说明书) for an initial public offering (IPO) of Jiangsu HOB Biotech Group Corp. It includes extensive information about the stock issuance, risk factors, financial data, company governance, and other disclosures typical of an IPO prospectus. The text mentions the issuance of new shares, listing on the STAR Market (科创板), underwriting details, risk disclosures, financial performance, and governance structure. This type of document is a formal offering document used to raise capital and provide investors with comprehensive information about the company and the offering. According to the filing definitions, this corresponds to a Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes. It is not an Annual Report, Earnings Release, or other report type. The document length and content confirm it is the full prospectus, not just an announcement or summary.
2021-01-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.